Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.
But the vascular disrupting agent’s unexpected success in a cancer indication might not be as resounding as it seems.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Key catalysts approach for Orphazyme, Gemini and Immutep.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
Demand for new issues remains sluggish - only eight private biotechs managed to pull off an IPO in the first quarter of 2017.